Results 1 to 10 of about 95,754 (365)

Primary biliary cholangitis

The Lancet, 2023
Primary biliary cholangitis is a chronic, autoimmune, cholestatic disease that mainly affects women aged 40-70 years. Recent epidemiological studies have shown an increasing incidence worldwide despite geographical heterogeneity and a decrease in the female-to-male ratio of those the disease affects.
Atsushi, Tanaka, Xiong, Ma, Atsushi, Takahashi, John M, Vierling   +3 more
semanticscholar   +16 more sources

Primary biliary cholangitis [PDF]

The Lancet, 2020
Primary biliary cholangitis is an autoimmune liver disease that predominantly affects women. It is characterised by a chronic and destructive, small bile duct, granulomatous lymphocytic cholangitis, with typical seroreactivity for antimitochondrial antibodies.
INSERM
  +12 more sources

Primary biliary cholangitis

Вестник трансплантологии и искусственных органов, 2021
Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is an organ-specific autoimmune disease predominantly affecting middle-aged women. It does not occur in children.
I. M. Iljinsky, O. M. Tsirulnikova
doaj   +6 more sources

Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis

The Korean Journal of Gastroenterology, 2020
Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are immune-mediated chronic liver diseases. PSC is a rare disorder characterized by multi-focal bile duct strictures and progressive liver diseases that ultimately results in the ...
Dong-Won Ahn
doaj   +3 more sources

A regulatory variant at 19p13.3 is associated with primary biliary cholangitis risk and ARID3A expression

Nature Communications, 2023
Primary biliary cholangitis is a rare, chronic immune-mediated liver disease triggered by environmental exposures in genetically susceptible individuals.
You Li, Zhiqiang Li, Ruiling Chen, Min Lian, Hanxiao Wang, Yiran Wei, Zhengrui You, Jun Zhang, Bo Li, Yikang Li, Bingyuan Huang, Yong Chen, Qiaoyan Liu, Zhuwan Lyu, Xueying Liang, Qi Miao, Xiao Xiao, Qixia Wang, Jingyuan Fang, YongYong Shi, Xiangdong Liu, Michael F. Seldin, M. Eric Gershwin, Ruqi Tang, Xiong Ma   +24 more
doaj   +2 more sources

Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis

Pathologica, 2021
Autoimmune cholestatic liver diseases are rare hepato-biliary disorders characterized by a progressive, inflammatory destruction of bile ducts. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are the main autoimmune cholestatic liver diseases. Both may evolve into secondary biliary cirrhosis and its complications. Therapeutic
Samantha Sarcognato, Diana Sacchi, Federica Grillo, Nora Cazzagon, Luca Fabris, Massimiliano Caldamuro, Ivana Catalso, Claudia Covelli, Alessandra Mangia, Maria Guido   +9 more
openaire   +5 more sources

Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics

Biomedicines, 2022
Cholangiopathies encompass various biliary diseases affecting the biliary epithelium, resulting in cholestasis, inflammation, fibrosis, and ultimately liver cirrhosis.
Ji-Won Park, Jung-Hee Kim, Sung-Eun Kim, Jang Han Jung, Myoung-Kuk Jang, Sang-Hoon Park, Myung-Seok Lee, Hyoung-Su Kim, Ki Tae Suk, Dong Joon Kim   +9 more
doaj   +2 more sources

Primary Biliary Cholangitis With Incomplete Response to Conventional Therapies But Had Complete Response to Baricitinib: A Case Report [PDF]

Case Reports in Hepatology
Primary biliary cholangitis is a progressive disease with complications such as liver cirrhosis and hepatocellular carcinoma, and the treatment goal is to delay its progression.
Gi Eun Kim, Mariam Imran, Sherif Mostafa, Yasser Kamel   +3 more
doaj   +2 more sources

Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult‐to‐treat primary biliary cholangitis

Alimentary Pharmacology and Therapeutics, 2021
Obeticholic acid (OCA) and fibrates are second‐line therapies for patients with primary biliary cholangitis (PBC) with an inadequate response to ursodeoxycholic acid (UDCA).
Pierre‐Antoine Soret, Laurent Lam, Fabrice Carrat, Lena Smets, Thomas Berg, Marco Carbone, Pietro Invernizzi, Vincent Leroy, Palak Trivedi, Nora Cazzagon, Christina Weiler‐Normann, Laurent Alric, Isabelle Rosa, Alexandra Heurgué, Jean‐Paul Cervoni, Jérôme Dumortier, Pascal Potier, Olivier Roux, Christine Silvain, Christophe Bureau, Rodolphe Anty, Dominique Larrey, Cynthia Levy, Albert Parés, Christoph Schramm, Frederik Nevens, Olivier Chazouillères, Christophe Corpechot   +27 more
openalex   +3 more sources

Baricitinib and primary biliary cholangitis

Journal of Translational Autoimmunity, 2021
Background and aims: There is an unmet need for alternative treatments for patients with primary biliary cholangitis (PBC) who do not respond to treatment with ursodeoxycholic acid (UDCA).
Stuart C. Gordon, Sheri Trudeau, Arie Regev, Jonathan M. Uhas, Sujatro Chakladar, Ana Pinto-Correia, Klaus Gottlieb, Doug Schlichting   +7 more
doaj   +3 more sources